INDIANAPOLIS, Dec. 27 -- Adding bevacizumab (Avastin) to paclitaxel (Taxol) prolonged progression-free survival as initial treatment for metastatic breast cancer, researchers said.   <READ MORE>

SAN ANTONIO, Dec. 17 -- Intravaginal testosterone may offer relief from atrophic vaginitis without the risks of estrogen to breast cancer patients taking aromatase inhibitors, according to a pilot study.   <READ MORE>

SAN ANTONIO, Dec. 17 -- A course of taxanes following standard anthracycline-based chemotherapy for breast cancer had no discernible benefit, found a large British study.  <READ MORE>

SAN ANTONIO, Dec. 17 -- Male breast cancer outcomes have improved substantially by earlier diagnoses and increased use of adjuvant therapies, two large French cohorts showed.   <READ MORE>

SAN ANTONIO, Dec. 13 -- The anthracycline drugs -- long a mainstay of breast cancer chemotherapy -- only benefit a minority of women and should be mostly scrapped, a researcher said here.   <READ MORE>

ROCKVILLE, Md., Dec. 4 -- Adding bevacizumab (Avastin) to paclitaxel (Taxol) for treatment of metastatic breast cancer did not extend overall survival, but did increase toxicity by more than 20% and mortality by 1.7%, FDA staffers said.   <READ MORE>

Thirty-Five Years Ago ... Approximately 75% of women diagnosed with breast cancer survived their disease at least 5 years.  <READ MORE>

BORDEAUX, France, Nov. 16 -- Gene-expression signatures in breast tumor samples can accurately predict which patients will not respond to two common chemotherapy regimens, researchers here found.  <READ MORE>

Washington, D.C. − A sophisticated microscope that offers a “real-time” 3-D analysis of tissue samples might, in the future, reduce the number of needle biopsies traditionally needed from women suspected of having breast cancer, according to recent research published at Georgetown University Medical Center’s Lombardi Comprehensive Cancer Center.  <READ MORE>

LOS ANGELES, Oct. 31 -- Two factors increase the risk of relapse after lumpectomy for early-stage breast cancer, but a boost of radiation aimed at the tumor bed lowers that risk, researchers reported here.  <READ MORE>

LOS ANGELES, Oct. 30 -- Black women with breast cancer are more likely to have a local relapse after a lumpectomy and radiation therapy than are white women, a researcher said here.  <READ MORE>

LOS ANGELES, Oct. 29 -- Smoking doesn't appear to affect the characteristics of breast tumors at diagnosis, a researcher said here.  <READ MORE>

ROCKVILLE, Md., Oct. 17 -- Bristol-Myers Squibb said its metastatic breast cancer drug ixabepilone (Ixempra) has received FDA approval for treatment of women with metastatic or locally advanced treatment-resistant breast cancer.  <READ MORE>

DURHAM, N.C., Oct. 12 --Oncologists need to think heart when treating early breast cancer, according to clinicians here.  <READ MORE>

One year after completing the first large-scale report sequencing breast and colon cancer genes, Johns Hopkins Kimmel Cancer Center scientists have studied the vast majority of protein-coding genes which now suggest a landscape dominated by genes that each are mutated in relatively few cancers.  <READ MORE>

BARCELONA, Spain, Sept. 26 -- The addition of trastuzumab (Herceptin) to chemotherapy before surgery appears to allow more women with HER-2 positive inflammatory breast cancer to achieve a complete disease response than does chemotherapy alone.  <READ MORE>

NEW YORK, Sept. 25 -- Proton magnetic resonance (MR) spectroscopy may eliminate 68% of biopsies for benign nonmass breast lesions found on standard MR imaging (MRI) without missing any cancers.   <READ MORE>

ROCKVILLE, Md., Sept. 17 -- The FDA has approved the osteoporosis drug raloxifene (Evista) for prevention of invasive breast cancer in high-risk or osteoporotic postmenopausal women.   <READ MORE>

SAN FRANCISCO, Sept. 12 -- Circulating tumor epithelial cells may open a window on the response of breast cancer to adjuvant therapy and, possibly, the risk of relapse as well, researchers said.   <READ MORE>

SAN FRANCISCO, Sept. 11 -- Neoadjuvant trastuzumab (Herceptin) may improve breast cancer response rates in combination with anthracycline-based chemotherapy, but some oncologists remain skeptical about cardiac toxicity.  <READ MORE>

SEATTLE, July 31 -- Screening MRI had a higher rate of breast cancer detection than either mammography or ultrasound screening in high-risk women, but it nearly quadrupled the biopsy rate, researchers here found.   <READ MORE>

ROCKVILLE, Md., July 25 -- An FDA advisory panel has recommended that the agency approve raloxifene (Evista) for prevention of breast cancer in high-risk postmenopausal women.   <READ MORE>

BOSTON, July 24 -- Only a minority of older breast cancer survivors undergoes recommended yearly surveillance mammography, but for those who do, the risk of dying from the disease is cut by almost a third, researchers found.   <READ MORE>

VANCOUVER, British Columbia, July 23 -- Systemic therapies for metastatic breast cancer introduced over the past decade appear to have improved survival, according to the first population-based study to support this long-suspected benefit.   <READ MORE>

ROCKVILLE, Md., July 16 -- The FDA has approved a rapid molecular-based test for detecting node-positive breast cancer.   <READ MORE>

HAIFA, Israel, July 11 -- Breast cancer survival was similar among carriers and noncarriers of BRCA1 and BRCA2 mutations in an Israeli study in which 10% of Ashkenazi women had such a susceptibility mutation, researchers reported.   <READ MORE>

For more about Denise and her Cancer Support Groups click here.

November 16, 2006 -Genentech, Inc. (NYSE: DNA) announced today that the U.S. Food and Drug Administration (FDA) approved Herceptin® (Trastuzumab), as part of a treatment regimen containing doxorubicin, ...  <READ MORE>

Previous Page